United Therapeutics Corporation Common Stock (UTHR)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at United Therapeutics, I see a specialty drug business focused on serious pulmonary and cardiovascular diseases. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $783.3 million and net income of $333.0 million, a 42.51% net margin. For FY2025, the year ended 2025-12-31, revenue was $3.2 billion, net income $1.3 billion, and diluted EPS $27.86, compared with FY2024 revenue $2.9 billion, net income $1.2 billion, and EPS $24.64. That long-term record supports FairStock's computed Lynch category of FAST GROWER, based on profit growth of 29.4% a year over four years and revenue growth of 17.2%. The balance sheet is a fortress: FairStock calculates debt-to-equity at 0.01 and Altman Z-score at 19.57. Returns are solid, with ROE of 19.31% and ROCE of 11.61%, while trailing free cash flow is $1.1 billion, a 4.7% FCF yield. But the latest filed quarter showed revenue down from $798.6 million in fiscal Q2 2025, the quarter ended 2025-06-30, even as net income rose from $309.5 million. The Piotroski F-score is 5/9, a mixed signal. Valuation is not Graham-cheap: at the 2026-10-13 close of $543.40, FairStock calculates a P/E of 19.48, P/B of 3.62, Graham Number of $306.83, and margin of safety of -77.10%, meaning the price is well above that asset-and-earnings benchmark. EV/EBITDA is 12.83. This is a high-quality, low-debt business with strong cash generation, but the current price already reflects much of that quality.

In plain English: United Therapeutics makes medicines for people with serious lung and heart-related diseases. The business earns strong profits and carries very little debt, but its most recent sales slipped from a year earlier even though profit rose. At the current share price, the stock looks closer to fair or a bit expensive when measured against the company’s earnings and accounting value, not clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer